101 related articles for article (PubMed ID: 15546202)
1. Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs.
Warnecke A; Fichtner I; Garmann D; Jaehde U; Kratz F
Bioconjug Chem; 2004; 15(6):1349-59. PubMed ID: 15546202
[TBL] [Abstract][Full Text] [Related]
2. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
3. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy.
Warnecke A; Kratz F
Bioconjug Chem; 2003; 14(2):377-87. PubMed ID: 12643748
[TBL] [Abstract][Full Text] [Related]
4. Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.
Pes L; Koester SD; Magnusson JP; Chercheja S; Medda F; Abu Ajaj K; Rognan D; Daum S; Nollmann FI; Garcia Fernandez J; Perez Galan P; Walter HK; Warnecke A; Kratz F
J Control Release; 2019 Feb; 296():81-92. PubMed ID: 30639692
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke A; Fichtner I; Sass G; Kratz F
Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
[TBL] [Abstract][Full Text] [Related]
6. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
7. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
Kratz F; Warnecke A; Scheuermann K; Stockmar C; Schwab J; Lazar P; Drückes P; Esser N; Drevs J; Rognan D; Bissantz C; Hinderling C; Folkers G; Fichtner I; Unger C
J Med Chem; 2002 Dec; 45(25):5523-33. PubMed ID: 12459020
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of anticancer activity of BOC26P, an ortho-aryl chalcone sodium phosphate as water-soluble prodrugs in vitro and in vivo.
Zhu C; Wang R; Zheng W; Chen D; Yue X; Cao Y; Qin W; Sun H; Wang Y; Liu Z; Li B; Du J; Bu X; Zhou B
Biomed Pharmacother; 2017 Dec; 96():551-562. PubMed ID: 29032339
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
Abu Ajaj K; Graeser R; Fichtner I; Kratz F
Cancer Chemother Pharmacol; 2009 Jul; 64(2):413-8. PubMed ID: 19229536
[TBL] [Abstract][Full Text] [Related]
10. Reactivity of novel albumin-binding platinum complexes.
Garmann D; Warnecke A; Kratz F; Jaehde U
Int J Clin Pharmacol Ther; 2004 Nov; 42(11):646-7. PubMed ID: 15598033
[No Abstract] [Full Text] [Related]
11. Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid.
Almotairy ARZ; Gandin V; Morrison L; Marzano C; Montagner D; Erxleben A
J Inorg Biochem; 2017 Dec; 177():1-7. PubMed ID: 28918353
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Berjeaud JM; Guilhot F; Papot S
J Med Chem; 2012 May; 55(9):4516-20. PubMed ID: 22515366
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog.
Wang Y; Jiang J; Jiang X; Cai S; Han H; Li L; Tian Z; Jiang W; Zhang Z; Xiao Y; Wright SC; Larrick JW
Bioorg Med Chem; 2008 Jul; 16(13):6552-9. PubMed ID: 18508273
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of Millepachine Amino Acid Prodrugs With Enhanced Solubility as Antitumor Agents.
Wu Y; Cao D; Wang F; Ma L; Gao G; Chen L
Chem Biol Drug Des; 2015 Oct; 86(4):559-67. PubMed ID: 25643726
[TBL] [Abstract][Full Text] [Related]
16. Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative.
Gust R; Schnurr B; Krauser R; Bernhardt G; Koch M; Schmid B; Hummel E; Schönenberger H
J Cancer Res Clin Oncol; 1998; 124(11):585-97. PubMed ID: 9860287
[TBL] [Abstract][Full Text] [Related]
17. Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands.
Fronik P; Poetsch I; Kastner A; Mendrina T; Hager S; Hohenwallner K; Schueffl H; Herndler-Brandstetter D; Koellensperger G; Rampler E; Kopecka J; Riganti C; Berger W; Keppler BK; Heffeter P; Kowol CR
J Med Chem; 2021 Aug; 64(16):12132-12151. PubMed ID: 34403254
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues.
Saha P; Descôteaux C; Brasseur K; Fortin S; Leblanc V; Parent S; Asselin E; Bérubé G
Eur J Med Chem; 2012 Feb; 48():385-90. PubMed ID: 22209414
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA).
Chung DE; Kratz F
Bioorg Med Chem Lett; 2006 Oct; 16(19):5157-63. PubMed ID: 16875815
[TBL] [Abstract][Full Text] [Related]
20. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
